{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:26:02Z","timestamp":1786998362030,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ymgme.2021.02.001","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T07:41:56Z","timestamp":1613893316000},"page":"234-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus"],"prefix":"10.1016","volume":"132","author":[{"given":"D.","family":"Moreno-Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Auray-Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Feriozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Langeveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.P.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pintos-Morell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Politei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rozenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Schiffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ymgme.2021.02.001_bb0005","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0015","series-title":"GeneReviews((R))","article-title":"Fabry disease","author":"Mehta","year":"1993"},{"issue":"3","key":"10.1016\/j.ymgme.2021.02.001_bb0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/humu.9172","article-title":"Molecular analysis in Fabry disease in Spain: Fifteen novel GLA mutations and identification of a homozygous female","volume":"22","author":"Rodr\u00edguez-Mar\u00ed","year":"2003","journal-title":"Hum. Mutat."},{"issue":"3","key":"10.1016\/j.ymgme.2021.02.001_bb0025","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/bbrc.1999.0310","article-title":"Fabry disease: identification of novel alpha-galactosidase a mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches","volume":"257","author":"Germain","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.ymgme.2021.02.001_bb0030","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.ymgme.2021.02.001_bb0035","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1161\/STROKEAHA.110.579409","article-title":"Belgian fabry study: prevalence of fabry disease in a cohort of 1000 young patients with cerebrovascular disease","volume":"41","author":"Brouns","year":"2010","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in north East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2021.02.001_bb0045","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","article-title":"The New York pilot newborn screening program for lysosomal storage diseases: report of the first 65,000 infants","volume":"21","author":"Wasserstein","year":"2019","journal-title":"Genet. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2021.02.001_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/jpc.12732","article-title":"Diagnostic dilemma and delay in Fabry disease: Insights from a case series of young female patients","volume":"51","author":"Ellaway","year":"2014","journal-title":"J. Paediatr. Child Health"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0055","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2013.09.008","article-title":"Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A)","volume":"426","author":"Liao","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0060","series-title":"New Drugs for the Treatment of Anderson\u2013Fabry Disease","author":"Feriozzi","year":"2020"},{"issue":"8","key":"10.1016\/j.ymgme.2021.02.001_bb0065","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ejim.2014.07.009","article-title":"Delphi consensus on the current clinical and therapeutic knowledge on Anderson-Fabry disease","volume":"25","author":"Concolino","year":"2014","journal-title":"Eur. J. Intern. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0075","series-title":"Uncertain Diagnosis of Fabry Disease in Patients With Neuropathic Pain, Angiokeratoma or Cornea Verticillata: Consensus on the Approach to Diagnosis and Follow-Up","first-page":"83","volume":"vol. 17","author":"van der Tol","year":"2014"},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0080","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ymgme.2014.08.007","article-title":"Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis","volume":"114","author":"van der Tol","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0085","series-title":"Fabry Disease: Developing Drugs for Treatment Guidance for Industry","volume":"FDA-2019-D-2973","author":"FDA","year":"2021"},{"issue":"4","key":"10.1016\/j.ymgme.2021.02.001_bb0090","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2307\/3150495","article-title":"The optimal number of response alternatives for a scale: a review","volume":"17","author":"Iii","year":"1980","journal-title":"J. Mark. Res."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0095","author":"Clinical Trials"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0100","author":"Clinical Trials"},{"issue":"1","key":"10.1016\/j.ymgme.2021.02.001_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2021.02.001_bb0110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ymgme.2021.02.001_bb0115","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in fabry disease a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"J. Am. Med. Assoc."},{"issue":"4","key":"10.1016\/j.ymgme.2021.02.001_bb0120","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.0022-202X.2004.22425.x","article-title":"Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies","volume":"122","author":"Thurberg","year":"2004","journal-title":"J. Investig. Dermatol."},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.ymgme.2021.02.001_bb0130","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.ymgme.2021.02.001_bb0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1023\/B:BOLI.0000009948.86528.72","article-title":"Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy","volume":"26","author":"Hajioff","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-2-4","article-title":"Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease","volume":"2","author":"Moore","year":"2002","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0150","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/hs0202.102601","article-title":"Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement","volume":"33","author":"Moore","year":"2002","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.ymgme.2021.02.001_bb0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.20550","article-title":"Enzyme replacement therapy and intraepidermal innervation density in Fabry disease","volume":"34","author":"Schiffmann","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0160","author":"Clinical Trials"},{"issue":"4","key":"10.1016\/j.ymgme.2021.02.001_bb0165","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0170","author":"Clinical Trials"},{"issue":"13","key":"10.1016\/j.ymgme.2021.02.001_bb0175","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/hc3801.096352","article-title":"Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in fabry disease: reversal by enzyme replacement therapy","volume":"104","author":"Moore","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0180","series-title":"Challenges of Developing and Conducting Clinical Trials in Rare Disorders","first-page":"773","author":"Kempf","year":"2018"},{"issue":"4","key":"10.1016\/j.ymgme.2021.02.001_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194494","article-title":"Characteristics of clinical trials in rare vs. common diseases: a register-based Latvian study","volume":"13","author":"Logviss","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-018320","article-title":"Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov","volume":"8","author":"Bothwell","year":"2018","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ymgme.2021.02.001_bb0195","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev-med-092012-112310","article-title":"Adaptive clinical trial design","volume":"65","author":"Chow","year":"2014","journal-title":"Annu. Rev. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2021.02.001_bb0200","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00415-004-0364-9","article-title":"Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease","volume":"251","author":"Hilz","year":"2004","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2021.02.001_bb0205","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular involvement in Fabry disease: current status of knowledge","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0210","first-page":"73","article-title":"Cognitive impairments and subjective cognitive complaints in Fabry disease: a nationwide study and review of the literature","volume":"41","author":"Loeb","year":"2018","journal-title":"JIMD Rep."},{"issue":"9499","key":"10.1016\/j.ymgme.2021.02.001_bb0215","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0220","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/STROKEAHA.112.663708","article-title":"Acute cerebrovascular disease in the young: the stroke in young Fabry patients study","volume":"44","author":"Rolfs","year":"2013","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.ymgme.2021.02.001_bb0225","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2215\/CJN.01820217","article-title":"Long-term dose-dependent agalsidase effects on kidney histology in fabry disease","volume":"12","author":"Skrunes","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ymgme.2021.02.001_bb0230","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ene.13775","article-title":"Genomic screening of Fabry disease in young stroke patients: the Taiwan experience and a review of the literature","volume":"26","author":"Lee","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0235","series-title":"Development and Clinical Consequences of White Matter Lesions in Fabry Disease: A Systematic Review","first-page":"205","author":"K\u00f6rver","year":"2018"},{"issue":"7","key":"10.1016\/j.ymgme.2021.02.001_bb0240","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jnnp-2019-322268","article-title":"Determinants of cerebral radiological progression in Fabry disease","volume":"91","author":"K\u00f6rver","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.ymgme.2021.02.001_bb0245","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0250","author":"Messroghli","year":"2017"},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0255","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0260","author":"Clinical Trials"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0265","series-title":"Early Biomarkers of Fabry Nephropathy: A Review of the Literature","first-page":"274","author":"Riccio","year":"2019"},{"issue":"1","key":"10.1016\/j.ymgme.2021.02.001_bb0270","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000369309","article-title":"Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria","volume":"129","author":"T\u00f8ndel","year":"2015","journal-title":"Nephron"},{"issue":"9","key":"10.1016\/j.ymgme.2021.02.001_bb0275","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/08860220903150296","article-title":"Kidney function and 24-hour proteinuria in patients with fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a brazilian experience","volume":"31","author":"Thofehrn","year":"2009","journal-title":"Ren. Fail."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0280","author":"FDA"},{"key":"10.1016\/j.ymgme.2021.02.001_bb0285","series-title":"Understanding the Gastrointestinal Manifestations of Fabry Disease: Promoting Prompt Diagnosis","first-page":"626","author":"Zar-Kessler","year":"2016"},{"issue":"1","key":"10.1016\/j.ymgme.2021.02.001_bb0290","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.ymgme.2021.02.001_bb0295","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry disease: practical recommendations for diagnosis and treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci. Ther."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2021.02.001_bb0300","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2021.02.001_bb0305","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.02.001_bb0310","article-title":"Globotriaosylsphingosine (lyso-Gb 3) and analogues in plasma and urine of patients with Fabry disease and correlations with long-term treatment and genotypes in a nationwide female Danish cohort","author":"Effraimidis","year":"2020","journal-title":"J. Med. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:27:11Z","timestamp":1761089231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221000354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1096719221000354"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.02.001","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}